The DOI matches its Crossref record; 462 of the 464 references it cites were found in a registry or an index.
Three Decades of β-Lactamase Inhibitors
Open accessAbstract
Since the introduction of penicillin, beta-lactam antibiotics have been the antimicrobial agents of choice. Unfortunately, the efficacy of these life-saving antibiotics is significantly threatened by bacterial beta-lactamases. beta-Lactamases are now responsible for resistance to penicillins, extended-spectrum cephalosporins, monobactams, and carbapenems. In order to overcome beta-lactamase-mediated resistance, beta-lactamase inhibitors (clavulanate, sulbactam, and tazobactam) were introduced into clinical practice. These inhibitors greatly enhance the efficacy of their partner beta-lactams (amoxicillin, ampicillin, piperacillin, and ticarcillin) in the treatment of serious Enterobacteriaceae and penicillin-resistant staphylococcal infections. However, selective pressure from excess antibiotic use accelerated the emergence of resistance to beta-lactam-beta-lactamase inhibitor combinations. Furthermore, the prevalence of clinically relevant beta-lactamases from other classes that are resistant to inhibition is rapidly increasing. There is an urgent need for effective inhibitors that can restore the activity of beta-lactams. Here, we review the catalytic mechanisms of each beta-lactamase class. We then discuss approaches for circumventing beta-lactamase-mediated resistance, including properties and characteristics of mechanism-based inactivators. We next highlight the mechanisms of action and salient clinical and microbiological features of beta-lactamase inhibitors. We also emphasize their therapeutic applications. We close by focusing on novel compounds and the chemical features of these agents that may contribute to a "second generation" of inhibitors. The goal for the next 3 decades will be to design inhibitors that will be effective for more than a single class of beta-lactamases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clavulanic acid, a potent β-lactamase inhibitor, was developed to overcome this limitation by binding irreversibly to the active site of β-lactamase enzymes, thereby protecting amoxicillin from enzymatic degradation and restoring its antimicrobial spectrum [3].”
From Clinical Outcomes and Real-World Effectiveness of Amoxicillin-Clavulanic Acid Across Indian Healthcare Settings: A Retrospective Multicenter Study (2026) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,495
Self-citationBradford, P. A. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.933-951.2001 · Cited by 2,646
Carbapenemases: the Versatile β-Lactamases
Queenan, A. M., & Bush, K. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00001-07 · Cited by 2,609
A functional classification scheme for beta-lactamases and its correlation with molecular structure
Bush, K., Jacoby, G. A., & Medeiros, A. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1211 · Cited by 2,485
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,328
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,277
Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
Pitout, J. D. D., & Laupland, K. B. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70041-0 · Cited by 2,068
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Nordmann, P., Cuzon, G., & Naas, T. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70054-4 · Cited by 1,619
Prevention of Drug Access to Bacterial Targets: Permeability Barriers and Active Efflux
Nikaido, H. (1994) · Science · doi:10.1126/science.8153625 · Cited by 1,542
Research works printed but not linked: 14
- Danel, F., M. G. Page, and D. M. Livermore. 2007. Class D β-lactamases, p. 163-194. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
- Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
- Dubus, A., P. Ledent, J. Lamotte-Brasseur, and J. M. Frere. 1996. The roles of residues Tyr150, Glu272, and His314 in class C β-lactamases. Proteins25:473-485.
- Foulds, G., W. E. Barth, J. R. Bianchine, A. R. English, D. Girard, S. L. Hayes, M. O'Brien, and P. Somani. 1980. Pharmacokinetics of CP-45.899 and pro-drug CP-47.904 in animals and humans, p. 353-356. In J. D. Nelson and C. Grassi (ed.), Current chemotherapy and infectious disease. American Society for Microbiology, Washington DC.
- Galleni, M., and J. M. Frere. 2007. Kinetics of β-lactamases and pencillin-binding proteins, p. 195-213. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washington, DC.
- F1-310. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
- F1-333a. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
- Livermore, D. M., M. Akova, P. J. Wu, and Y. J. Yang. 1989. Clavulanate and β-lactamase induction. J. Antimicrob. Chemother.24(Suppl. B):23-33.
- A1-006. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. 2009
- Meroueh, S., J. Cha, and S. Mobashery. 2007. Inhibition of class A β-lactamases, p. 101-114. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for inhibition. ASM Press, Washingtion, DC.
- Page, M. G. 2007. Resistance mediated by penicllin-binding proteins, p. 81-99. In R. A. Bonomo and M. E. Tolmasky (ed.), Enzyme-mediated resistance to antibiotics: mechanisms, dissemination, and prospects for Inhibition. ASM Press, Washington, DC.
- F1-311. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
- F1-0882. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. 2007
- Slocombe, B., A. S. Beale, R. J. Boon, K. E. Griffin, P. J. Masters, R. Sutherland, and A. R. White. 1984. Antibacterial activity in vitro and in vivo of amoxicillin in the presence of clavulanic acid, p. 29-49. InProgress and perspectives on β-lactamase inhibition: a review of Augmentin. Custom Communications: Postgraduate Medicine, New York, NY.
Cited by
Sorted by citations
Items 101–200 of 1,001
Management of bacterial and fungal infections in cirrhosis: The MDRO challenge
Fernández, J., Piano, S. S., Bartoletti, M., & Wey, E. Q. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.010 · Cited by 174
Antibiotic Adjuvants: A Versatile Approach to Combat Antibiotic Resistance
Dhanda, G., Acharya, Y., & Haldar, J. (2023) · ACS Omega · doi:10.1021/acsomega.3c00312 · Cited by 170
Venkateswaran, P., Vasudevan, S., David, H., Shaktivel, A., Shanmugam, K., Neelakantan, P., & Solomon, A. P. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1159798 · Cited by 181
New β-Lactamase Inhibitors in the Clinic
Papp‐Wallace, K. M., & Bonomo, R. A. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.007 · Cited by 164
Self-citationScandorieiro, S., de Camargo, L. C., Lancheros, C. A. C., Yamada‐Ogatta, S. F., Nakamura, C. V., de Oliveira, A. G., Andrade, C. G. T. J., Durán, N., Nakazato, G., & Kobayashi, R. K. T. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00760 · Cited by 172
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Membrane‐Active Small Molecules: Designs Inspired by Antimicrobial Peptides
Ghosh, C., & Haldar, J. (2015) · ChemMedChem · doi:10.1002/cmdc.201500299 · Cited by 155
Papp‐Wallace, K. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1660772 · Cited by 156
The Continuing Challenge of Metallo-β-Lactamase Inhibition: Mechanism Matters
Ju, L.-C., Cheng, Z., Fast, W. L., Bonomo, R. A., & Crowder, M. W. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.007 · Cited by 155
Self-citationβ-lactam/β-lactamase inhibitor combinations: an update
Tehrani, K. H. M. E., & Martin, N. I. (2018) · MedChemComm · doi:10.1039/c8md00342d · Cited by 153
Pérez, F., Chakhtoura, N. G. E., Papp‐Wallace, K. M., Wilson, B. M., & Bonomo, R. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1145658 · Cited by 151
Self-citationEbselen as a potent covalent inhibitor of New Delhi metallo-β-lactamase (NDM-1)
Chiou, J. A., Wan, S., Chan, K., So, P., He, D., Chan, E. W., Chan, T. H., Wong, K., Jiang, T., & Chen, S. (2015) · Chemical Communications · doi:10.1039/c5cc02594j · Cited by 150
Touchet, S., Carreaux, F., Carboni, B., Bouillon, A., & Boucher, J. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00154f · Cited by 149
Avershina, E., Shapovalova, V., & Shipulin, G. A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.707330 · Cited by 157
A Common Platform for Antibiotic Dereplication and Adjuvant Discovery
Cox, G., Sieron, A. O., King, A. M., Pascale, G. D., Pawlowski, A. C., Koteva, K. K., & Wright, G. D. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.11.011 · Cited by 146
Overcoming differences: The catalytic mechanism of metallo‐β‐lactamases
Meini, M.-R., Llarrull, L. I., & Vila, A. J. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.08.015 · Cited by 145
Stachyra, T., Péchereau, M.-C., Bruneau, J., Claudon, M., Frère, J., Miossec, C., Coleman, K., & Black, M. T. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00568-10 · Cited by 145
(2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.masthead.30-1 · Cited by 145
Winkler, M., Papp‐Wallace, K. M., Hujer, A. M., Domitrovic, T., Hujer, K. M., Hurless, K. N., Tuohy, M. J., Hall, G. S., & Bonomo, R. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04238-14 · Cited by 143
Self-citationInsight into the amoxicillin resistance, ecotoxicity, and remediation strategies
Sodhi, K. K., Kumar, M., & Singh, D. K. (2020) · Journal of Water Process Engineering · doi:10.1016/j.jwpe.2020.101858 · Cited by 147
Wright, G. D. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.10.019 · Cited by 143
Assay Platform for Clinically Relevant Metallo-β-lactamases
van Berkel, S. S., Brem, J., Rydzik, A. M., Salimraj, R., Cain, R. M., Verma, A. K., Owens, R. J., Fishwick, C. W. G., SPENCER, J. M., & Schofield, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400769b · Cited by 138
Discovery of Wall Teichoic Acid Inhibitors as Potential Anti-MRSA β-Lactam Combination Agents
Wang, H., Gill, C., Lee, S. H., Mann, P. A., Zuck, P. D., Meredith, T. C., Murgolo, N., She, X., Kales, S., Liang, L., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.11.013 · Cited by 136
Kanj, S. S., Bassetti, M., Kiratisin, P., Rodrigues, C. S., Villegas, M. V., Yu, Y., & van Duin, D. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106633 · Cited by 143
Labby, K. J., & Garneau‐Tsodikova, S. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.80 · Cited by 140
Tängdén, T., Hickman, R. A., Forsberg, P., Lagerbäck, P., Giske, C. G., & Cars, O. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00741-13 · Cited by 132
Zhang, H., Nengzi, L., Li, X., Wang, Z., Li, B., Liu, L., & Cheng, X. (2020) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.124011 · Cited by 132
The Road to Avibactam: The First Clinically Useful Non-β-Lactam Working Somewhat Like a β-Lactam
Wang, D. Y., Abboud, M. I., Markoulides, M. S., Brem, J., & Schofield, C. J. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0078 · Cited by 129
Kim, S. W., Park, S. B., Im, S. P., Lee, J., Jung, J. W., Gong, T. W., Lazarte, J. M. S., Kim, J., Seo, J., Kim, J.-H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23656-0 · Cited by 127
New β‐lactam–β‐lactamase inhibitor combinations in clinical development
Shlaes, D. M. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12010 · Cited by 130
Cyclic Boronates Inhibit All Classes of β-Lactamases
Cahill, S. T., Cain, R. M., Wang, D. Y., Lohans, C. T., Wareham, D. W., Oswin, H. P., Mohammed, J., Spencer, J., Fishwick, C. W. G., McDonough, M. A., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02260-16 · Cited by 128
Genetic basis of molecular mechanisms in β-lactam resistant gram-negative bacteria
Hussain, H. I., Aqib, A. I., Seleem, M. N., Shabbir, M. A. B., Hao, H., Iqbal, Z., Kulyar, M. F., Zaheer, T., & Li, K. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105040 · Cited by 128
Taking aim at wall teichoic acid synthesis: new biology and new leads for antibiotics
Sewell, E. W., & Brown, E. D. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.100 · Cited by 128
Look and Outlook on Enzyme-Mediated Macrolide Resistance
Golkar, T., Zieliński, M., & Berghuis, A. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01942 · Cited by 126
A Concise Synthesis of a β-Lactamase Inhibitor
Mangion, I. K., Ruck, R. T., Rivera, N. R., Huffman, M. A., & Shevlin, M. (2011) · Organic Letters · doi:10.1021/ol202195n · Cited by 125
New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams
Vázquez-Ucha, J. C., Arca-Suárez, J., Bou, G., & Beceiro, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239308 · Cited by 125
Livermore, D. M., Day, M. J., Cleary, P. R., Hopkins, K. L., Toleman, M. A., Wareham, D. W., Wiuff, C., Doumith, M., & Woodford, N. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky453 · Cited by 124
An overview of cephalosporin antibiotics as emerging contaminants: a serious environmental concern
Das, N., Madhavan, J., Selvi, A., & Das, D. (2019) · 3 Biotech · doi:10.1007/s13205-019-1766-9 · Cited by 124
Saravanan, M., Ramachandran, B., & Barabadi, H. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.11.061 · Cited by 121
Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations
Papp‐Wallace, K. M., Mack, A. R., Taracila, M. A., & Bonomo, R. A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.001 · Cited by 123
Self-citationPFunkel: Efficient, Expansive, User-Defined Mutagenesis
Firnberg, E., & Ostermeier, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052031 · Cited by 121
Status report on carbapenemases: challenges and prospects
Patel, G., & Bonomo, R. A. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.28 · Cited by 121
Self-citationHan, F., Liu, X., Wang, S., Fleming, J., Wang, D., & Liu, W. (2017) · Nature Communications · doi:10.1038/s41467-017-02339-w · Cited by 121
Tsivkovski, R., Totrov, M. M., & Lomovskaya, O. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00130-20 · Cited by 121
β-Lactam/β-Lactamase Inhibitor Combinations: From Then to Now
Toussaint, K. A., & Gallagher, J. C. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014556652 · Cited by 136
Antisense antimicrobial therapeutics
Sully, E. K., & Geller, B. L. (2016) · Current Opinion in Microbiology · doi:10.1016/j.mib.2016.05.017 · Cited by 120
Menz, B. D., Charani, E., Gordon, D. L., Leather, A. J., Moonesinghe, S. R., & Phillips, C. J. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s319780 · Cited by 118
Chandorkar, G., Huntington, J. A., Gotfried, M. H., Rodvold, K. A., & Umeh, O. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks246 · Cited by 118
Barnes, M. D., Taracila, M. A., Rutter, J. D., Bethel, C. R., Galdadas, I., Hujer, A. M., Caselli, E., Prati, F., Dekker, J. P., Papp‐Wallace, K. M., et al. (2018) · mBio · doi:10.1128/mbio.02085-18 · Cited by 118
Self-citationClass D β-Lactamases: A Reappraisal after Five Decades
Leonard, D. A., Bonomo, R. A., & Powers, R. A. (2013) · Accounts of Chemical Research · doi:10.1021/ar300327a · Cited by 123
Self-citationDevelopment of New Drugs for an Old Target — The Penicillin Binding Proteins
Zervosen, A., Sauvage, E., Frère, J., Charlier, P., & Luxen, A. (2012) · Molecules · doi:10.3390/molecules171112478 · Cited by 117
Structural and Mechanistic Insights into NDM-1 Catalyzed Hydrolysis of Cephalosporins
Han, F., Ding, J., Zhu, D., Liu, X., Xu, X., Zhang, Y., Zang, S., Wang, D., & Liu, W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja508388e · Cited by 115
Metallo-ß-lactamases: a review
Behzadi, P., García‐Perdomo, H. A., Karpiński, T. M. M., & Issakhanian, L. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05651-9 · Cited by 115
Remote, Late-Stage Oxidation of Aliphatic C–H Bonds in Amide-Containing Molecules
Nanjo, T., Júnior, E. C. D. L., & White, M. C. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b07665 · Cited by 114
Li, L., Li, Z., Shi, W. S., Li, X., & Ma, H. (2014) · Analytical Chemistry · doi:10.1021/ac501288e · Cited by 113
Wang, C., Wei, X., Zhong, L., Chan, C.-L., Li, H., & Sun, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c16035 · Cited by 118
Gangadharappa, B. S., Sharath, R., Revanasiddappa, P. D., Chandramohan, V., Balasubramaniam, M., & Vardhineni, T. P. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1667265 · Cited by 113
β-Lactamases identified in clinical isolates ofPseudomonas aeruginosa
Zhao, W., & Hu, Z. (2010) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2010.481763 · Cited by 110
Veeraraghavan, B., Bakthavatchalam, Y., & Anandan, S. (2016) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.176149 · Cited by 110
Lee, S. H., Wang, H., Labroli, M. A., Koseoglu, S., Zuck, P. D., Mayhood, T., Gill, C., Mann, P. A., Sher, X., Ha, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7364 · Cited by 110
Interaction of Avibactam with Class B Metallo-β-Lactamases
Abboud, M. I., Damblon, C., Brem, J., Smargiasso, N., Mercuri, P. S., Gilbert, B., Rydzik, A. M., Claridge, T. D. W., Schofield, C. J., & Frère, J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00897-16 · Cited by 110
Thinking Outside the Bug: Molecular Targets and Strategies to Overcome Antibiotic Resistance
Monserrat‐Martinez, A., Gambin, Y., & Sierecki, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061255 · Cited by 116
Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition
King, D. T., King, A. M., Lal, S. M., Wright, G. D., & Strynadka, N. C. J. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00007 · Cited by 113
Liu, X., Shi, Y., Kang, J. S., Oelschlaeger, P., & Yang, K. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00098 · Cited by 109
Sharma, R., Park, T. E., & Moy, S. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.018 · Cited by 108
Microbial Resistance to Antibiotics and Effective Antibiotherapy
Chiş, A. A., Rus, L. L., Morgovan, C., Arseniu, A. M., Frum, A., Vonica-Țincu, A. L., Gligor, F. G., Mureșan, M.-L., & Dobrea, C. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051121 · Cited by 132
Kim, Y., Tesar, C., Mire, J., Jedrzejczak, R. P., Binkowski, A., Babnigg, G., Sacchettini, J. C., & Joachimiak, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024621 · Cited by 108
Improving Antibiotic Activity against Wound Pathogens with Manuka Honey In Vitro
Jenkins, R., & Cooper, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045600 · Cited by 107
How antibiotics work together: molecular mechanisms behind combination therapy
Sullivan, G. J., Delgado, N. N., Maharjan, R. P., & Cain, A. K. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.05.012 · Cited by 107
Polymyxins and their novel derivatives
Vaara, M. (2010) · Current Opinion in Microbiology · doi:10.1016/j.mib.2010.09.002 · Cited by 107
A β‐Lactamase‐Imprinted Responsive Hydrogel for the Treatment of Antibiotic‐Resistant Bacteria
Li, W., Dong, K., Ren, J., & Qu, X. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201600205 · Cited by 106
New strategies for targeting and treatment of multi-drug resistant Staphylococcus aureus
Assis, L. M., Nedeljković, M., & Dessen, A. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.03.001 · Cited by 104
New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108
Variants of β-Lactamase KPC-2 That Are Resistant to Inhibition by Avibactam
Papp‐Wallace, K. M., Winkler, M., Taracila, M. A., & Bonomo, R. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04406-14 · Cited by 105
Self-citationAntibacterial and β‐Lactamase Inhibitory Activity of Monocyclic β‐Lactams
Decuyper, L., Jukič, M., Sosič, I., Žula, A., D’hooghe, M., & Gobec, S. (2017) · Medicinal Research Reviews · doi:10.1002/med.21443 · Cited by 105
A neutral diphosphate mimic crosslinks the active site of human O-GlcNAc transferase
Jiang, J., Lazarus, M. B., Pasquina, L. W., Piotr Sliz, A., & Walker, S. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.711 · Cited by 106
Postgenomic Strategies in Antibacterial Drug Discovery
Brötz‐Oesterhelt, H., & Saß, P. (2010) · Future Microbiology · doi:10.2217/fmb.10.119 · Cited by 103
Can β-Lactam Antibiotics Be Resurrected to Combat MRSA?
Foster, T. J. (2018) · Trends in Microbiology · doi:10.1016/j.tim.2018.06.005 · Cited by 106
Exploring the Role of a Conserved Class A Residue in the Ω-Loop of KPC-2 β-Lactamase
Levitt, P. S., Papp‐Wallace, K. M., Taracila, M. A., Hujer, A. M., Winkler, M., Smith, K. M., Xu, Y., Harris, M. E., & Bonomo, R. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348540 · Cited by 103
Self-citationYang, L., Zhang, S., Chen, Z., Wen, Q., & Wang, Y. (2016) · Bioresource Technology · doi:10.1016/j.biortech.2016.01.004 · Cited by 102
Resistance drives antibacterial drug development
Theuretzbacher, U. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.07.008 · Cited by 101
An insight into medicinal attributes of dithiocarbamates: Bird’s eye view
Shinde, S. D., Sakla, A. P., & Shankaraiah, N. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104346 · Cited by 100
Compain, F., & Arthur, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00451-17 · Cited by 101
Boron-Containing heterocycles as promising pharmacological agents
Das, B. C., Shareef, M. A., Das, S., Nandwana, N. K., Das, Y., Saito, M., & Weiss, L. M. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116748 · Cited by 102
Mechanistic and Spectroscopic Studies of Metallo-β-lactamase NDM-1
Yang, H., Aitha, M., Hetrick, A., Richmond, T. K., Tierney, D. L., & Crowder, M. W. (2012) · Biochemistry · doi:10.1021/bi300056y · Cited by 100
Venter, H. (2019) · Bioscience Reports · doi:10.1042/bsr20180474 · Cited by 97
Engineering consortia by polymeric microbial swarmbots
Wang, L., Zhang, X., Tang, C., Li, P., Zhu, R., Sun, J., Zhang, Y., Cui, H., Ma, J., Song, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31467-1 · Cited by 99
Bioinformatics of antimicrobial resistance in the age of molecular epidemiology
McArthur, A. G., & Wright, G. D. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.07.004 · Cited by 98
Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors
Brem, J., Panduwawala, T., Hansen, J. U., Hewitt, J. F. M., Liepinsh, E., Donets, P. A., Espina, L., Farley, A. J. M., Shubin, K. M., Gómez‐Campillos, G., et al. (2021) · Nature Chemistry · doi:10.1038/s41557-021-00831-x · Cited by 97
Antibiotic adjuvants: identification and clinical use
Bernal, P., Molina‐Santiago, C., Daddaoua, A., & Llamas, M. A. (2013) · Microbial Biotechnology · doi:10.1111/1751-7915.12044 · Cited by 101
Suppressive drug combinations and their potential to combat antibiotic resistance
Singh, N. P., & Yeh, P. J. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.102 · Cited by 94
Will morphing boron-based inhibitors beat the β-lactamases?
Krajnc, A., Lang, P. A., Panduwawala, T., Brem, J., & Schofield, C. J. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.03.001 · Cited by 97
Mojica, M. F., Rutter, J. D., Taracila, M. A., Abriata, L. A., Fouts, D. E., Papp‐Wallace, K. M., Walsh, T. J., LiPuma, J. J., Vila, A. J., & Bonomo, R. A. (2019) · mBio · doi:10.1128/mbio.00405-19 · Cited by 97
Self-citationThe global need for effective antibiotics—Moving towards concerted action
Cars, O., Hedin, A., & Heddini, A. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.006 · Cited by 97
Hubbard, A. T. M., Mason, J., Roberts, P., Parry, C. M., Corless, C. E., van Aartsen, J. J., Howard, A., Bulgasim, I., Fraser, A. J., Adams, E. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18668-2 · Cited by 96
Antimicrobial agents targeting bacterial cell walls and cell membranes
Bush, K. (2012) · Scientific and Technical Review (World Organisation for Animal Health) · doi:10.20506/rst.31.1.2096 · Cited by 96
Single-molecule theory of enzymatic inhibition
Robin, T., Reuveni, S., & Urbakh, M. (2018) · Nature Communications · doi:10.1038/s41467-018-02995-6 · Cited by 99
Acquired Bacterial Resistance to Antibiotics and Resistance Genes: From Past to Future
Galgano, M., Pellegrini, F., Catalano, E., Capozzi, L., Sambro, L. D., Sposato, A., Lucente, M. S., Vasinioti, V. I., Catella, C., Odigie, A. E., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14030222 · Cited by 121
Antibiotic resistance by enzyme inactivation: From mechanisms to solutions
De Pascale, G., & Wright, G. D. (2010) · ChemBioChem · doi:10.1002/cbic.201000067 · Cited by 94
Bonnin, R. A., Jousset, A. B., Emeraud, C., Oueslati, S., Dortet, L., & Naas, T. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.616490 · Cited by 94
Metadata
- Authors
- Drawz, S. M., & Bonomo, R. A.
- Affiliations
- Departments of Pathology
- United States Department of Veterans Affairs (US)
- Corresponding author
- Bonomo, Robert A.
- ORCID
- Bonomo, Robert A.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 23
- Issue
- 1
- Pages
- 160-201
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- PMC
- PMC2806661
- OpenAlex
- W1895007034
- Cited by
- 1,709
- References
- 464
- Citations by year
- 2026: 83 · 2025: 100 · 2024: 87 · 2023: 86 · 2022: 106 · 2021: 126 · 2020: 151 · 2019: 130 · 2018: 131 · 2017: 119 · 2016: 120 · 2015: 108 · 2014: 93 · 2013: 88 · 2012: 81
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Microbiology Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (1R01A1063517-01)
- National Institute of General Medical Sciences (T32GM007250, T32GM07250)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis of β-Lactam Compounds
- Keywords
- beta-lactamase inhibitors, beta-lactamase, beta-lactam resistance, clavulanic acid, sulbactam, tazobactam, mechanism-based inactivators, carbapenemase inhibitors, extended-spectrum cephalosporin resistance, Enterobacteriaceae, penicillin-resistant staphylococci
- MeSH terms
- Bacteria, Bacterial Infections, Bacterial Proteins, beta-Lactamases, Enzyme Inhibitors, Humans, beta-Lactam Resistance, beta-Lactamase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
